Palliadelic Treatment to Reduce Psychological Distress in Persons With Inoperable Pancreatobiliary Cancer

Pancreas Cancer Clinical Trial

Official title:

An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress and Improve Quality of Life in Persons With Pancreatobiliary Cancer, With a Parallel Assessment of Healthcare Utilization and Family Wellbeing

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05220046
• Other study ID #: 0860-21-FB
• Status: Recruiting
• Phase: Phase 1
• Start date: April 10, 2023
• Est. completion date: July 2025

Study information

• Verified date: January 2024
• Source: University of Nebraska
• Contact: Evelyn Cantril
• Phone: 402-559-5923
• Email: ecantril[@]unmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the ability to recruit and retain participants, and to successfully conduct a psilocybin-based protocol, for a study of the treatment of distress related to inoperable pancreatobilliary cancer. Secondary objectives include pre/post, and longitudinal measurement of distress in intervention participants and a paired family member who is in an observational arm.

Description:

Participants with unresectable pancreas or biliary tract cancers are eligible for intervention, paired family member recruited for observational arm. Following preparatory sessions in outpatient palliative care clinic or by telehealth (2-4 sessions lasting 60-90 minutes each), psilocybin will be administered as a 25mg capsule during an 8-hour monitored session. Integration sessions (2-3 sessions lasting up to 90 minutes each) will take place in the outpatient palliative care clinic or by phone or tele-heath. Primary and secondary objectives are complete at one-week post treatment, longitudinal exploratory measures collected up to 12 months post baseline. Parallel assessment of health care utilization, including choices regarding anti-cancer treatment and resource utilization, and family member distress, family communication, well-being and bereavement will be conducted at concurrent time points.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: July 2025
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 85 Years

Eligibility

Inclusion Criteria:

1. For participants with a diagnosis unresectable pancreatic or biliary tract cancer (gallbladder adenocarcinoma, cholangiocarcinoma, ampullary adenocarcinoma carcinoma), do they have a non-zero score on the NCCN Distress Thermometer?

2. Is the participant between the ages of 19 and 85?

3. Does the subject have unresectable pancreatic or biliary tract cancer (gallbladder adenocarcinoma, cholangiocarcinoma, ampullary adenocarcinoma carcinoma)?

4. Is the participant English speaking?

5. Does the participant have an ECOG performance status of 0-3?

6. Does the participant have a life expectancy = 8 weeks as determined by referring oncologist?

7. Does the participant have the ability to provide written informed consent and comply with study procedures?

8. Is the participant aware of the neoplastic and likely incurable nature of his/her disease?

9. Does the participant have one family member willing to participate in measures?

10. Is the participant (male and female) of childbearing potential (defined as age <55 and menses within the prior 2 years with intact ovaries and uterus) agreeable to use an adequate method of contraception or birth control from the time of enrollment to 24 hours following the psilocybin session?

Exclusion Criteria:

1. Does the participant have severe symptoms of depression or anxiety warranting immediate treatment with antidepressant or anxiolytic medications or preventing safe discontinuation of those medications for the psilocybin session?

2. Is the participant suicidal, noted by a history of suicide attempt within 2 years or high-risk of suicide as measured by Columbia Suicide Severity?

3. Does the participant have a current or prior history of schizophrenia, psychotic disorder (unless substance induced or due to medical condition) or bipolar I or II disorder?

4. Does the participant have a first-degree family member with schizophrenia, psychotic disorder (unless substance induced or due to medical condition) or bipolar I or II disorder?

5. Does the participant have any conditions known to be incompatible with establishment of rapport or safe exposure to psilocybin including dissociative disorder, anorexia nervosa, bulimia nervosa?

6. Does the participant have alcohol or recreational drug abuse disorder, excluding caffeine and nicotine?

7. Does the participant have known CNS metastases or other major CNS disease such as seizure disorder, dementia, Parkinson's disease, multiple sclerosis?

8. Is the participant receiving treatment in another clinical trial involving an investigational product for the treatment of cancer?

9. Does the participant have Hepatic dysfunction as indicated by the following values:

Alkaline phosphatase:> 3 X upper limit of normal (ULN) AST: > 3 X ULN ALT:> 3 X ULN Total bilirubin: > 3 X ULN

10. Does the participant have Renal dysfunction as indicated by creatinine clearance <40 ml/min using the Cockroft-Gault equation?

11. Does the participant have cardiac or circulatory dysfunction defined as: uncontrolled hypertension (systolic blood pressure > 140 or diastolic blood pressure >90 mmHg on three separate readings), angina, stroke or myocardial infarction in the prior 6 months, claudication?

12. Does the participant have a history of seizures?

13. Is the participant unable to skip a meal (lunch), or diabetes which requires administration of medication more than twice daily, or with symptomatic hypoglycemia within the prior 30 days?

14. Female participants only: Is the participant pregnant or breastfeeding?

15. Is the participant currently using any of the following potent metabolic inducers or inhibitors? Inducers: rifampin, rifabutin, rifapentine, carbamazepine, phenytoin, phenobarbital, nevirapine, efavirenz, St. Johns Wort. Paclitaxel and dexamethasone are permitted if 5 half-lives have passed between last dose and psilocybin session Inhibitors: All HIV protease inhibitors, itraconazole, ketoconazole, erythromycin, clarithromycin, troleandomycin

16. MMRI exclusions: Metal in body (i.e. hearing aid, cardiac pacemaker, bone plates, braces, non-removeable piercings/implants, etc.) claustrophobia, inability to lay still for one-hour, or any other condition that would preclude MRI scanning?

Related Conditions & MeSH terms

• Biliary Tract Cancer
• Biliary Tract Neoplasms
• Pancreas Cancer
• Pancreatic Neoplasms
• Psychological Distress

Intervention

Drug:
• Psilocybin
Psilocybin, 25mg administered orally drug during an 8-hour monitored session with supportive pre- and post- session counseling

Locations

Country	Name	City	State
United States	University of Nebraska Medical Center	Omaha	Nebraska

Sponsors (2)

Lead Sponsor	Collaborator
University of Nebraska	Nebraska University Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recruitment Rate	Number of participants enrolled/ number approached.	18 months
Primary	Retention Rate	Number of participants who complete the psilocybin session and the assessments at 8-12 days post-psilocybin session/ total enrolled	24 months
Secondary	Change in Patient Health Questionnaire-9 (PHQ-9) Depression Scale total score from Baseline to 1 week post-dose	Patient Health Questionnaire-9 (PHQ-9) is a nine-item, 32 point scale of frequency of common depressive symptoms. Higher score indicates worse depression.	Baseline; Day 8-11 post-dose
Secondary	Change in General Anxiety DIsorder-7 (GAD-7) total score from Baseline to 1 week post-dose	Change in General Anxiety DIsorder-7 (GAD-7) is a 7 item, 21 scale to measure frequency of common symptoms of anxiety with higher score indicating higher severity.	Baseline; Day 8-11 post-dose
Secondary	Change in Demoralization Scale (D-II) total score from Baseline to 1 week post-dose	Change in Demoralization Scale (D-II) is a 16 item, 32 point scale with two factors, meaning & purpose and distress & coping, that measures frequency of symptoms of demoralization and existential distress, with higher score indicating higher severity.	Baseline; Day 8-11 post-dose